Cellectis S.A.

Lasme-cel's phase 2 data in relapsed/refractory ALL show promising CR/CRi rates, and key 2025 pipeline readouts across a larger patient population signal meaningful clinical progress for Cellectis's lead allogeneic CAR-T programs, supporting an upward sentiment revision.

Despite encouraging early data, pivotal readout timelines for lasme-cel remain unclear, and the broader Cellectis pipeline is still largely in Phase 1 or earlier stages, making any near-term approval catalyst highly speculative and difficult to price with confidence.

Cellectis holds a strong cash position that extends its runway into H2 2027, providing sufficient financial stability to advance key pipeline programs and reach critical clinical milestones without immediate pressure to raise capital.

Analyst consensus forecasts show Cellectis remaining deeply unprofitable through at least 2028, with projected losses of up to $179 million. The current cash runway is likely insufficient to fund full approval and commercialization, making dilutive financing nearly inevitable.

The global CAR-T cell therapy market, valued at $11.26 billion in 2025 and projected to grow at a 36.67% CAGR through 2034, offers a massive addressable opportunity for Cellectis. Analysts maintain a consensus Buy rating with an average price target of $7.67, implying over 500% upside.

Following a 150% stock rally, Cellectis's current valuation is seen as outpacing near-term catalysts. With revenue growth forecast at just 9.1% per year — slower than both the broader US market and high-growth biotech peers — the risk/reward profile has deteriorated significantly at current price levels.